Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.47 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.44 |
| ▸ | ACACB | O00763 | 9/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ACACA | Q13085 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9888804 | 0.86 | ALDH1A1 (0.42) | TAS1R3TAS1R1TAS1R2ALDH1A1MTNR1A | |
| SCHEMBL2736111 | 0.83 | MTNR1A (0.43) | ALDH1A1MTNR1AMTNR1BACACBACACA | |
| SCHEMBL13242519 | 0.81 | GABRP (0.43) | ALDH1A1MTNR1AMTNR1BACACB | |
| SCHEMBL18531990 | 0.81 | MTNR1A (0.42) | ALDH1A1MTNR1AMTNR1BACACBACACA | |
| SCHEMBL7890560 | 0.80 | — | — | |
| SCHEMBL13932519 | 0.80 | — | — | |
| SCHEMBL8435514 | 0.80 | — | — | |
| SCHEMBL18520329 | 0.80 | — | — | |
| SCHEMBL13452338 | 0.80 | — | — | |
| SCHEMBL8142982 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857605-B2 | Thiosuccinyl-crosslinked hemoglobin conjugates and methods of use and preparation thereof | BILLION KING INTERNATIONAL LIMITED (CN) | 2024-01-02 | — | — | US | disclosed |
| US-11692022-B2 | Thiosuccinyl-crosslinked hemoglobin analogs and methods of use and preparation thereof | BILLION KING INTERNATIONAL LIMITED (CN) | 2023-07-04 | — | — | US | disclosed |
| US-20220177486-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. | 2022-06-09 | — | — | US | disclosed |
| WO-2021042890-A1 | HETEROCYCLIC COMPOUND AND APPLICATION THEREOF AS TRK KINASE INHIBITOR | 罗欣药业(上海)有限公司 | 2021-03-11 | — | — | WO | disclosed |
| US-7598244-B2 | [1,2,4]triazolo[1,5,a]pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2009-10-06 | — | — | US | disclosed |
| US-7598244-B2 | [1,2,4]triazolo[1,5,a]pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2009-10-06 | — | — | US | disclosed |
| US-7517875-B2 | Piperidine derivatives having CCR3 antagonism | TEIJIN LIMITED (JP) | 2009-04-14 | — | — | US | disclosed |
| US-7517875-B2 | Piperidine derivatives having CCR3 antagonism | TEIJIN LIMITED (JP) | 2009-04-14 | — | — | US | disclosed |
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | HLA-C, TPMT, TAP1 | TAS1R3 785/4885TAS1R1 221/4885TAS1R2 698/4885 |
| US-11692022-B2 | Thiosuccinyl-crosslinked hemoglobin analogs and methods of use and preparation thereof | HBG1, HBG2, HBB | TAS1R3 1574/4885TAS1R1 2128/4885TAS1R2 1996/4885 |
| US-11857605-B2 | Thiosuccinyl-crosslinked hemoglobin conjugates and methods of use and preparation thereof | HBG1, HBG2, HBB | TAS1R3 2395/4885TAS1R1 2917/4885TAS1R2 2663/4885 |
| US-20220177486-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | TAS1R3 1800/4885TAS1R1 1498/4885TAS1R2 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.